Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
21 studies found for:    ETV6
Show Display Options
Rank Status Study
1 Unknown  Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias
Conditions: Hypereosinophilic Syndrome;   Chronic Eosinophilic Leukemia (CEL);   Myeloproliferative Disorders
Intervention: Drug: STI571
2 Recruiting Evaluating the Safety and Tolerability of Etravirine in HIV-1 Infected Infants and Children
Condition: HIV Infections
Intervention: Drug: Etravirine (ETR)
3 Completed
Has Results
Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.
Condition: HIV
Intervention: Drug: TMC125, Darunavir; Ritonavir
4 Completed
Has Results
A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).
Condition: HIV-1 Infection
Intervention: Drug: TMC125; darunavir; ritonavir
5 Completed Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz
Condition: Sleep Disorders
Interventions: Drug: etravirine;   Drug: efavirenz
6 Completed
Has Results
A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced Patients
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: Etravirine;   Drug: Ritonavir;   Drug: Darunavir
7 Withdrawn Maraviroc Versus Etravirine In Combination With Antiretroviral Therapy In Drug Experienced HIV And Hepatitis Co-Infected Patients
Conditions: Hepatitis B;   Human Immunodeficiency Virus;   Hepatitis C, Chronic
Interventions: Drug: maraviroc;   Drug: etravirine
8 Terminated Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 100 mg once daily;   Drug: GSK2248761 200 mg once daily;   Drug: Etravirine
9 Completed Dose Ranging Study of Pegylated Interferon Lambda in Patients With Hepatitis B and Positive for the Hepatitis B e Antigen
Condition: Hepatitis B Virus
Interventions: Drug: pegIFN;   Drug: pegIFNα-2a;   Drug: PegIFN lambda;   Drug: Entecavir
10 Completed Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine
Condition: HIV
Interventions: Drug: Etravirine;   Drug: Darunavir/ritonavir;   Drug: artemether/lumefantrine
11 Active, not recruiting Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection
Condition: Chronic Hepatitis B
Interventions: Drug: entecavir;   Drug: Other anti-HBV medication
12 Completed
Has Results
Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B
Condition: Hepatitis B, Chronic
Interventions: Drug: Entecavir;   Drug: Entecavir + Tenofovir
13 Active, not recruiting
Has Results
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection
Condition: Hepatitis B, Chronic
Intervention: Drug: Entecavir
14 Active, not recruiting
Has Results
A Phase III Study of the Safety and Efficacy of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus Infection
Condition: Chronic Hepatitis B Virus, Pediatric
Interventions: Drug: Entecavir;   Drug: Placebo
15 Completed Maintenance Boosted Lopinavir Monotherapy Following Salvage Protease-inhibitor (PI) Based Regimen in HIV With Non-nucleoside Reverse Transcriptase Inhibitors (NNRTI) Based Regimen Failure
Conditions: HIV;   AIDS;   Lopinavir;   Treatment Failure
Interventions: Drug: Ritonavir-boosted lopinavir;   Drug: optimized background regimens (OBRs)
16 Completed GSK1349572 Drug Interaction Study With Efavirenz
Conditions: Infections, Human Immunodeficiency Virus and Herpesviridae;   Healthy
Interventions: Drug: GSK1349572;   Drug: Efavirenz
17 Active, not recruiting Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B
Condition: Chronic Viral Hepatitis B Without Delta-agent
Interventions: Drug: Tenofovir;   Drug: Entecavir
18 Active, not recruiting Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B
Condition: Chronic Viral Hepatitis B Without Delta-agent
Interventions: Drug: Tenofovir;   Drug: Entecavir
19 Recruiting Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B
Condition: Chronic Hepatitis B
Intervention: Drug: Pegasys&Entecavir
20 Active, not recruiting
Has Results
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir
Condition: HIV Infection
Interventions: Drug: Elvitegravir;   Drug: Raltegravir;   Drug: Placebo to match elvitegravir;   Drug: Placebo to match raltegravir;   Drug: Background regimen

   Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results    Last Page
Indicates status has not been verified in more than two years